Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin in symptomatic benign prostatic hyperplasia
NCT04107896Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of silodosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoints: International Prostate Symptom Score at 12 weeks and Quality of Life Score at 12 weeks. Started Aug 2017; status: completed.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04107896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107896.